Anti-human SMIM45-107aa monoclonal antibody and application thereof

By developing high specificity and high affinity anti-human SMIM45-107aa monoclonal antibody, the problem of lacking high specificity and high affinity in the prior art was solved, and effective immune detection of tumor tissues is achieved, suitable for a variety of cancers Sample detection.

CN119080935AActive Publication Date: 2024-12-06SHANGHAI TONGREN HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411418103.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-11
Publication Date
2024-12-06
Estimated Expiration
2044-10-11

AI Technical Summary

Technical Problem

The lack of high specificity and high affinity anti-human SMIM45-107aa monoclonal antibody in the prior art makes it difficult to effectively use for immunoassay in tumor tissues.

Method used

A monoclonal antibody against human SMIM45-107aa was developed to immunize mice through the full length of the amino acid of human SMIM45-107aa protein as an immunogen. Heavy and light chain sequences were obtained using single B cell screening and culture technology, and combined with constant The region is IgG4, achieving high specificity for binding to SMIM45-107aa protein.

Benefits of technology

The obtained antibodies have high specificity and high affinity and are suitable for immunologic detection, such as immunohistochemistry, immunoblotting and immunofluorescence detection, ensuring the sensitivity and reliability of the detection. They are suitable for liver cancer, gastric cancer, breast cancer and intrahepatic bile ducts. Cancer sample detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080935A_ABST
    Figure CN119080935A_ABST
Patent Text Reader

Abstract

The invention discloses an anti-human SMIM45-107aa monoclonal antibody and application of the anti-human SMIM45-107aa monoclonal antibody. The anti-human SMIM45-107aa monoclonal antibody can be specifically combined with SMIM45-107aa; in the monoclonal antibody, the sequence of a heavy chain variable region CDR-H1 is as shown in SEQ ID No.3, the sequence of a heavy chain variable region CDR-H2 is as shown in SEQ ID No.4, the sequence of a heavy chain variable region CDR-H3 is as shown in SEQ ID No.5, the sequence of a light chain variable region CDR-L1 is as shown in SEQ ID No.6, the sequence of a light chain variable region CDR-L2 is as shown in SEQ ID No.7, and the sequence of a light chain variable region CDR-L3 is as shown in SEQ ID No.8. The anti-human SMIM45-107aa monoclonal antibody prepared by the invention has high specificity, can specifically recognize cells containing SMIM45-107aa protein, and is suitable for immunological detection, such as immunohistochemistry, immunoblotting and immunofluorescence detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to an anti-human SMIM45-107aa monoclonal antibody and a use thereof. Background Art

[0002] Small integral membrane protein 45 (SMIM45-107aa) is a polypeptide protein encoded by LINC00634, which is a small molecular weight integral membrane protein and encodes 107 amino acids. This type of protein usually has one or more transmembrane domains and plays an important role in cell signaling, cell-cell interactions, and maintaining cell structure. Compared with normal tissues, the expression level of LINC00634 in tumor tissues is higher, such as liver cancer and colorectal cancer, but the role and mechanism of the encoded SMIM45-107aa polypeptide in tumors have not been reported.

[0003] In recent years, lincRNA-encoded polypeptides have gradually become a research hotspot, playing a key role in the occurrence and development of diseases. These polypeptides can act as carcinogenic factors or tumor suppressor factors to affect the progression of the disease. Therefore, these polypeptides can be used as therapeutic targets for tumors, and targeted antibody drugs can be developed for carcinogenic factors. With the progress of immunotherapy and targeted therapy in tumor treatment, the use of antibody drugs for targeted therapy has broad application prospects.

[0004] Due to the potential role of SMIM45-107aa in liver cancer, monoclonal antibodies against this protein have important research and therapeutic value. However, there are currently no human-mouse cross-reactive, highly specific monoclonal antibodies against SMIM45-107aa that can be used in immunoassay applications. Summary of the invention

[0005] The purpose of the present invention is to provide an anti-human SMIM45-107aa monoclonal antibody and its use in view of the deficiencies in the prior art.

[0006] To achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect is to provide an anti-human SMIM45-107aa monoclonal antibody, comprising a heavy chain variable region and a light chain variable region, and the antibody can specifically bind to SMIM45-107aa; in the monoclonal antibody, the amino acid sequence of the heavy chain variable region CDR-H1 is shown as SEQ ID No.3, the amino acid sequence of the heavy chain variable region CDR-H2 is shown as SEQ ID No.4, the amino acid sequence of the heavy chain variable region CDR-H3 is shown as SEQ ID No.5, the amino acid sequence of the light chain variable region CDR-L1 is shown as SEQ ID No.6, the amino acid sequence of the light chain variable region CDR-L2 is shown as SEQ ID No.7, and the amino acid sequence of the light chain variable region CDR-L3 is shown as SEQ ID No.8.

[0008] Furthermore, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.1, and the amino acid sequence of the light chain variable region is shown as SEQ ID No.2.

[0009] Furthermore, the amino acid sequence of the heavy chain of the monoclonal antibody is shown in SEQ ID No.9, and the amino acid sequence of the light chain is shown in SEQ ID No.10.

[0010] Furthermore, the heavy chain and the light chain both include a constant region, and the constant region is a constant region of mouse or human IgG, preferably a constant region of IgG4.

[0011] The second aspect is to provide a nucleotide molecule composition, including a nucleotide molecule as shown in the sequence SEQ ID NO:11, and a nucleotide molecule as shown in the sequence SEQ ID NO:12; wherein the sequence SEQ ID NO:11 encodes the heavy chain variable region of the above-mentioned monoclonal antibody; the sequence SEQ ID NO:12 encodes the light chain variable region of the above-mentioned monoclonal antibody.

[0012] The third aspect is to provide an expression vector comprising the above-mentioned nucleotide molecule composition.

[0013] The fourth aspect is to provide a host cell comprising the above expression vector, wherein the host cell is a eukaryotic cell, preferably a mammalian cell.

[0014] The fifth aspect is to provide the application of the above-mentioned monoclonal antibodies in the preparation of liver cancer, gastric cancer, breast cancer and intrahepatic bile duct cancer sample detection products.

[0015] The sixth aspect is to provide a detection product, comprising the above-mentioned monoclonal antibody, and the detection product is selected from the group consisting of detection reagents, kits, immunohistochemistry detection and immunoblotting detection.

[0016] The present invention adopts the above technical solution, and has the following technical effects compared with the prior art:

[0017] The present invention selects the full length of the amino acid of human SMIM45-107aa protein as an antigen, and the protein expressed after coupling with His is an immunogen. Mice are immunized with the immunogen, and the mouse monoclonal antibody and heavy chain and light chain sequences of the SMIM45-107aa protein are obtained based on the single B cell screening and cultivation monoclonal antibody development technology. The anti-human SMIM45-107aa monoclonal antibody prepared by the present invention has high specificity, can specifically identify cells containing SMIM45-107aa protein, and is suitable for immunological detection, such as immunohistochemistry, immunoblotting and immunofluorescence detection. In addition, the anti-human SMIM45-107aa monoclonal antibody has a high affinity with human SMIM45-107aa, ensuring the sensitivity and reliability in various immunological detections. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The results are shown in Figure 1 and 10 for analyzing serum titers from two immunized mice using ELASA.

[0019] Figure 2 The results are shown in Figure 1, which are the results of MBC sorting using flow cytometry.

[0020] Figure 3 The results are shown in Figure 2, which show the purity of SMIM45-107aa antibody detected by SDS-PAGE gel.

[0021] Figure 4 Western blot was used to detect the expression of anti-SMIM45-107aa monoclonal antibody in liver cancer tissues.

[0022] Figure 5 IHC was used to detect the expression of anti-SMIM45-107aa monoclonal antibody in liver cancer tissues.

[0023] Figure 6 IHC was used to detect the expression of anti-SMIM45-107aa monoclonal antibody in gastric cancer, breast cancer and intrahepatic cholangiocarcinoma tissues.

[0024] Figure 7 Immunocytofluorescence detection of the cellular localization of SMIM45-107aa in liver cancer cells. DETAILED DESCRIPTION

[0025] The first aspect of the present invention protects an anti-human SMIM45-107aa monoclonal antibody, comprising a heavy chain variable region and a light chain variable region, and the antibody can specifically bind to SMIM45-107aa; in the monoclonal antibody, the amino acid sequence of the heavy chain variable region CDR-H1 is shown as SEQ ID No.3, the amino acid sequence of the heavy chain variable region CDR-H2 is shown as SEQ ID No.4, the amino acid sequence of the heavy chain variable region CDR-H3 is shown as SEQ ID No.5, the amino acid sequence of the light chain variable region CDR-L1 is shown as SEQ ID No.6, the amino acid sequence of the light chain variable region CDR-L2 is shown as SEQ ID No.7, and the amino acid sequence of the light chain variable region CDR-L3 is shown as SEQ ID No.8.

[0026] In certain embodiments, the amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown as SEQ ID No.1, and the amino acid sequence of the light chain variable region is shown as SEQ ID No.2.

[0027] The amino acid sequence of the heavy chain of the monoclonal antibody is shown in SEQ ID No.9, and the amino acid sequence of the light chain is shown in SEQ ID No.10.

[0028] Preferably, both the heavy chain and the light chain further comprise a constant region, which is a constant region of mouse or human IgG, more preferably a constant region of IgG4.

[0029] The specific sequence of the anti-human SMIM45-107aa monoclonal antibody of the present invention is as follows:

[0030] 1) Heavy chain variable region amino acid sequence (the underlined region is the heavy chain CDR region):

[0031] MDSRLNLVFLVLILKGVQCDVQLVES GGGLVQPGGSRK LSCAASGFTFSS FGMH WVRQAPEKGLE WVAYINFGSSTIYYADTVKGRFTISRDNPKNTLFLQM TS LRSEDTAMYYCVR CYGNYYAMDYWGQGTSVTVSS(SEQID NO:1)

[0032] CDR-H1 GGGLVQPGGSRK(SEQ ID NO:3)

[0033] CDR-H2 WVRQAPEKGLE(SEQ ID NO:4)

[0034] CDR-H3 LRSEDTAMYYCVR(SEQ ID NO:5)

[0035] 2) Light chain variable region amino acid sequence: (The underlined region is the light chain CDR region)

[0036] MDMRTPAQFLGILLLWFPGIKCDIKM TQSPSSMYASLG ERVTITCNASHDI NSYL SWFQQKPGKS PKTLIYRTNRLVDGVPSRFSGSGSGQDYSLTISSLEYED M GIYYCLQYDEFP LTFGAGTKLELK (SEQ ID NO: 2)

[0037] CDR-L1 TQSPSSMYASLG(SEQ ID NO:6)

[0038] CDR-L2 SWFQQKPGKS(SEQ ID NO:7)

[0039] CDR-L3 MGIYYCLQYDEFP(SEQ ID NO:8)

[0040] 3) Heavy chain amino acid sequence:

[0041] MDSRLNLVFLVLILKGVQCDVQLVESGGGLVQPGGSRKLSCAASGFTFSSFGM

[0042] HWVRQAPEKGLEWVAYINFGSSTIYYADTVKGRFTISRDNPKNTLFLQMTSLR

[0043] SEDTAMYYCVRCYGNYYAMDYWGQGTSVTVSSAKTTPPSVYPLAPGSAAQT

[0044] NSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPS

[0045] STWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKD

[0046] VLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRS

[0047] VSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKE

[0048] QMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK(SEQ ID NO:9)

[0049] 4) Light chain amino acid sequence:

[0050] MDMRTPAQFLGILLLWFPGIKCDIKMTQSPSSMYASLGERVTITCNASHDINSY

[0051] LSWFQQKPGKSPKTLIYRTNRLVDGVPSRFSGSGSGQDYSLTISSLEYEDMGIY

[0052] YCLQYDEFPLTFGAGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFY

[0053] PKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC(SEQ ID NO:10)

[0054] The second aspect of the present invention protects a nucleotide molecule composition, including a nucleotide molecule as shown in the sequence SEQ ID NO:11, and a nucleotide molecule as shown in the sequence SEQ ID NO:12; wherein the sequence SEQ ID NO:11 encodes the heavy chain variable region of the above-mentioned monoclonal antibody; the sequence SEQ ID NO:12 encodes the light chain variable region of the above-mentioned monoclonal antibody.

[0055] Heavy chain variable region nucleic acid sequence:

[0056] ATGGACTCCAGGCTCAATTTAGTTTTCCTTGTCCTTATTTTAAAAGGTGTCCAGTGTGATGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGCAGCCTGGAGGGTCCCGGAAACTCTCCTGTGCAGCCTCTGGATTCACTTTCAGTAGCTTTGGAATGCACTGGGTTCGTCAGGCTCCAGAGAAGGGGCTGGAGTGGGTCGCATACATTAATTTTGGCAGTAGTACCATCTACTATGCAGACACAGTGAAGGGCCGATTCACCATCTCCAGAGACAATCCCAAGAACACCCTGTTCCTGCAAATGACCAGTCTAAGGTCTGAGGACACGGCCATGTACTACTGTGTAAGATGTTATGGTAACTACTATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA(SEQ ID NO:11)

[0057] Light chain variable region nucleic acid sequence:

[0058] ATGGACATGAGGACCCCTGCTCAGTTTCTTGGAATCTTGTTGCTCTGGTTTCCAGGTATCAAATGTGACATCAAGATGACCCAGTCTCCATCTTCCATGTATGCATCTCTAGGAGAGAGAGTCACTATCACTTGCAATGCGAGTCACGACATTAATAGCTATTTAAGCTGGTTCCAGCAGAAACCAGGGAAATCTCCTAAGACCCTGATCTATCGTACAAACAGATTGGTAGATGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTATGAAGATATGGGAATTTATTATTGTCTACAGTATGATGAGTTTCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAAA(SEQ ID NO:12)

[0059] The third aspect of the present invention protects an expression vector, comprising the above-mentioned nucleotide molecule composition. The construction method of the expression vector should be known to those skilled in the art. For example, the expression vector can be constructed by in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology and other methods. The expression vector in the present invention generally refers to various commercially available expression vectors well known in the art, such as bacterial plasmids, bacteriophages, yeast plasmids, plant cell viruses, mammalian cell viruses such as adenoviruses, retroviruses or other vectors.

[0060] The fourth aspect of the present invention protects a host cell containing the above expression vector, wherein the host cell is a eukaryotic cell, preferably a mammalian cell. The construction method thereof should be known to those skilled in the art, for example, it may be a combination of one or more of microinjection, gene gun, electroporation, virus-mediated transformation, electron bombardment, calcium phosphate precipitation, etc., but not limited to.

[0061] The fifth aspect of the present invention protects the use of the above-mentioned monoclonal antibody in the preparation of liver cancer detection products.

[0062] The sixth aspect of the present invention protects a detection product, comprising the above-mentioned monoclonal antibody, and the detection product is selected from the group consisting of a detection reagent, a test kit, a chip and a membrane strip.

[0063] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments, but is not intended to be limiting of the present invention. It should be noted that the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict. The test methods in the following embodiments that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by various manufacturers.

[0064] Example 1 Obtaining a mouse monoclonal antibody specific for SMIM45-107aa by the SingleB rapid monoclonal method

[0065] 1.1 Animal immunization

[0066] Step 1: Immunize mice according to the common method in the literature (E Harlow, D. Lane, Antibody: Laboratory Manμal, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998). Recombinant human SMIM45-107aa (wherein the hμman SMIM45-107aa protein sequence is selected as ... amino acid sequence) is used as the immunogen.

[0067] Step 2: Rapid immune adjuvants are used to increase immune response, immunization and enhance immunity. Briefly, the antigen protein solution is prepared with PBS, the adjuvant and antigen are thoroughly mixed at a volume ratio of 1:1, and then injected into mice.

[0068] Step 3: Serum titer detection: After the final immunization, a small amount of tail blood is collected and the serum titer is determined by indirect ELISA.

[0069] 1) Antigen coating: dilute the antigen to 2 μg / ml with PBS buffer, add 100 μl per well to a 96-well ELISA plate, and incubate overnight at 4°C. Wash the coated ELISA plate 3 times with a plate washer and tap dry, add 100 μl of blocking solution per well, incubate in a 37°C incubator for 2 hours, and then wash the blocked ELISA plate 3 times with a plate washer and tap dry.

[0070] 2) Incubation with primary antibody: Dilute the sera of immune mice and non-immune mice (serum of non-immune mice is a negative control) with PBS buffer at dilution ratios of 1:1000, 1:2000, 1:4000, 1:8000, 1:16000, 1:32000, 1:64000, 1:128000, 1:256000, and 1:512000. Add 100 μl of the diluted sera to the corresponding wells and incubate at 37°C for 1 h. After incubation, place the ELISA plate in a plate washer and wash it three times.

[0071] 3) Incubation with secondary antibody: Add 100 μl of HRP-labeled goat anti-mouse secondary antibody to the corresponding wells, incubate at 37°C for 30 min, and wash the ELISA plate three times in a plate washer.

[0072] 4) Color development: Add the mixed color development solution to the 96-well plate, 100 μl per well, and incubate at 37°C for 15 min.

[0073] 5) Stop and read: Add stop solution to the 96-well plate, 100 μl per well, and then place it in an ELISA reader for reading. The detection wavelength is set to 450 nm. Read the test results. OD values ​​greater than 2.1 times that of the negative control are considered positive. Figure 1 .

[0074] Step 4: According to the results of serum titer determination, 2 to 3 booster immunizations are usually required after the first immunization to achieve a good immune effect. Select immunized mice with high serum titers for intraperitoneal injection as the last booster immunization before sorting.

[0075] 1.2 Producing monoclonal antibodies by in vitro expansion of single B cells

[0076] Step 1, preparation of single cell suspension: before sorting B cells, kill the immunized mice, take the mouse spleen in a sterile environment, and remove the surrounding connective tissue. Place the spleen on a cell filter, gently press the spleen with a syringe needle to obtain a cell suspension, take Ficoll-Paqμe PLμS cell separation solution and cell suspension at a volume ratio of 1:2 and add them to a test tube, 1500rpm, 15 minutes, the middle layer of the test tube after centrifugation is generally a mononuclear cell layer, aspirate the mononuclear cell layer, add SOL024 solution, 1500rpm, 10 minutes, remove the supernatant after centrifugation, add 500μL SOL024 solution to resuspend the cells.

[0077] Step 2: MBC sorting by flow cytometry: Using the property that BCR on the surface of MBC can specifically bind to antigenic proteins, the antigenic proteins are fluorescently labeled, and the MBCs that specifically bind to antigenic proteins can be sorted out one by one from the cell suspension by flow cytometry. The sorting results are shown in Figure 2 .

[0078] Step 3: DNA cloning and sequencing, and anti-SMIM45-107aa antibody sequence analysis.

[0079] Step 4: Total RNA was extracted from single B cells using TRIZOL reagent (Invitrogen, cat#15596-018). Briefly, 5*10 6 Transfer the cells to a 1.5ml centrifuge tube and dry the supernatant. Add 600μl of TRIZOL reagent and blow, let stand at room temperature for 10 minutes to lyse the cells. Add 120μl of chloroform to each tube, shake vigorously for 30 seconds, let stand at room temperature for 10 minutes, and centrifuge at 4℃12000g for 15 minutes. Pipette the upper solution and transfer it to a new centrifuge tube, add an equal volume of isopropanol to mix, and place on ice for 20 minutes to precipitate RNA. Then centrifuge at 4℃ and 12000g for 15 minutes, remove the supernatant, leave the precipitate at the bottom of the tube, and add pre-cooled 75% ethanol to wash twice. Finally, dry at room temperature for 5 minutes to evaporate the residual ethanol, and add 30μl of DEPC-treated water to dissolve the RNA.

[0080] Step 5. Use Takara's reverse transcription kit (cat#6110A) to reverse transcribe RNA into cDNA. The experimental system is as follows: 1μg of total RNA (about 3μl), 1μl of Oligo (dT) primer, add water (RNase-free water) to 10μl, react at 65°C for 5 minutes and immediately cool on ice. Subsequently, add 4μl of 5*PrimeScript Bμffer, 0.5μl of RNaseInhibitor, 1μl of PrimeScript RTase, add water (RNase-free water) to 20μl, mix slowly, and reverse transcribe according to the following conditions: 42°C, 30-60min; keep warm at 95°C for 5min to complete cDNA synthesis. Further, poly-G was added to the 3' end of the cDNA. The reaction system was prepared as follows: 5 μl of cDNA, 33.5 μl of ddH2O, 5 μl of 10*TdT buffer, 5 μl of CoCl2, 1 μl of dGTP, 0.5 μl of terminal deoxynucleotidyl transferase (total volume 50 μl), incubated at 37°C for 30 min, and then at 70°C for 10 min to complete poly-G tailing.

[0081] Step six, use the tailed cDNA as a template to amplify the gene of the antibody variable region. For amplifying the antibody heavy chain variable region sequence, prepare the PCR reaction system: 10*Taq enzyme buffer 5μl, universal poly C primer (forward primer) 0.5μl, mouse IgG reverse primer 0.5μl, dNTP 1μl, Taq polymerase 1μl, cDNA 1μl, ddH2O 41μl. The conditions for PCR amplification of the antibody heavy chain and light chain variable regions are as follows: 1) pre-denaturation 95℃, 5min; 2) denaturation 95℃, 20sec; 3) annealing 58℃, 15sec; 4) extension 72℃, 30sec; 5) storage at 20℃, 60min

[0082] The PCR products were analyzed by 1.5% agarose gel electrophoresis, and the corresponding bands were cut out (VH 414 bp, VK 387 bp), and the Fab region fragments of the heavy chain and light chain were obtained using the Tiangen Bio-Gel Recovery Kit.

[0083] Step 7, construct expression plasmid and transfection: connect the amplified paired antibody light and heavy chain Fab base sequences to the pcDNA3.4 vector containing the mouse IgG1 Fc fragment to construct the light and heavy chain recombinant expression plasmids. Use a commercial plasmid extraction kit to extract the plasmid. For specific steps, refer to the plasmid extraction instructions in each kit.

[0084] Step 8: Transient Expression

[0085] 1) Cells were seeded one day before transfection to ensure that the cells grew to 3.0-5.0×10 6 cells / mL, viability 98%, the cell suspension was diluted with culture medium and plated in 96 deep-well plates, 400 μl per well.

[0086] 2) Spread the transfection buffer into a 96-well plate, 100 μl per well, then add the plasmid into the transfection buffer and pipette to mix, then add PEI max into the buffer and pipette to mix, incubate at 37°C for 10 min, and add to the 96-deep-well plate cells for continued culture.

[0087] 3) 20 hours after transfection, add 25 μl of feed to each well. After 4-5 days of expression, centrifuge at 4000 rpm for 10 minutes and collect the supernatant.

[0088] Step 9: ELISA test of cell supernatant and selection of candidate clones. Indirect ELISA test of cell supernatant to see if it is positive:

[0089] 1) Antigen coating: dilute the antigen to 2 μg / ml with PBS buffer, add 100 μl per well to a 96-well ELISA plate, and incubate overnight at 4°C. Wash the coated ELISA plate 3 times with a plate washer and tap dry, add 100 μl of blocking solution per well, incubate in a 37°C incubator for 2 hours, and then wash the blocked ELISA plate 3 times with a plate washer and tap dry.

[0090] 2) Incubate with primary antibody: Place 50 μl of cell supernatant in each well, take the same amount of immune serum as positive control, and PBS buffer as negative control, and incubate at 37°C for 1 hour. After incubation, wash the ELISA plate in a plate washer 3 times and dry it.

[0091] 3) Incubation with secondary antibody: Add 100 μl of HRP-labeled goat anti-mouse secondary antibody to the corresponding wells, incubate at 37°C for 30 min, wash the ELISA plate three times in a plate washer and dry.

[0092] 4) Color development: Add the mixed color development solution to the 96-well plate, 100 μl per well, and incubate at 37°C for 15 min.

[0093] 5) Stop and read: Add stop solution to the 96-well plate, 50 μl per well, and then place it in an ELISA reader for reading. Set the detection wavelength to 450 nm and read the test results. An OD value greater than 2.1 times that of the negative control well is considered positive.

[0094] The serum titers of 20 candidate positive clones (1M1E1, 1M1C3, 1M1E3, 1M1G3, 1M1G4, 1M1G7, 1M1B8, 1M1C10, 1M1D10, 1M1B12, 1M1D12, 1M1F12, 1M3A2, 1M3A3, 1M3D4, 1M3C8, 1M3C9, 1M3D10, 1M3A11, 1M3C12) were tested, and the results are shown in Table 1. 1M3C8 with the highest serum titer was selected for expression and purification, and the antibody was used for subsequent functional verification.

[0095] Table 1

[0096]

[0097]

[0098] Step 10: Antibody expression and purification

[0099] 1) Transient expression of expression plasmid The selected clone 1M3C8 was expressed using the same steps as above.

[0100] 2) Antibody purification: The cell culture fluid after transfection and culture for 6 days was centrifuged, and the secretion supernatant after centrifugation was filtered with a filter membrane, dialyzed into a buffer solution at 4°C, and purified with a Protein A column after dialysis. The purity was >90%.

[0101] 3) SDS-PAGE gel detection of SMIM45-107aa antibody purity: Prepare SDS-PAGE gel: Install vertical electrophoresis equipment; prepare 15% lower separation gel, place at room temperature for 30 minutes to wait for gel polymerization; prepare 5% upper concentration gel, insert a 10-hole comb and wait for it to solidify and polymerize; Loading: Add the prepared sample with SDS-loading buffer to the gel well; Electrophoresis: 80V constant voltage for 10 minutes, then switch to 120V constant voltage for 60 minutes. Coomassie Brilliant Blue Staining: After the electrophoresis is completed, stain with Coomassie Brilliant Blue dye for 30 minutes; Decolorization: After decolorization with decolorization solution, take pictures and save. Figure 3 The results showed that the purified SMIM45-107aa antibody had two clear bands, namely the heavy chain and the light chain, with almost no mixed bands, indicating that the purified SMIM45-107aa antibody had a high purity.

[0102] Example 2 Detection of SMIM45-107aa monoclonal antibody specificity using western blot, IHC and immunofluorescence

[0103] 2.1 Western blot was used to analyze the expression of SMIM45-107aa in liver cancer tissue samples and cell samples. Simply, SDS-PAGE gel was prepared; loading: the prepared sample with SDS loading buffer was added to the gel well; electrophoresis: 80V constant voltage for 10min, then 9 to 120V constant voltage for 60min; transfer: wet transfer method was used, and the membrane was transferred in the order of sponge-filter paper-gel-membrane-filter paper-sponge, and the membrane was transferred at 280mA constant current for 60min; incubation with antibodies: 5% milk was blocked for 1 hour; diluted primary antibody (1:1000) was added and incubated for 2 hours; after rinsing the membrane 5 times, goat anti-mouse secondary antibody was added at a ratio of 1:5000 and incubated for 1 hour; development: positive energy development was used for imaging and preservation. Figure 4 The results showed that SMIM45-107aa monoclonal antibody had clear bands in purified SMIM45-107aa protein samples, SK-Hep1 liver cancer cells overexpressing SMIM45-107aa, and liver cancer tissue samples, indicating that SMIM45-107aa antibody can recognize SMIM45-107aa natural antigen.

[0104] 2.2 Functional identification and application of SMIIM45 using IHC:

[0105] Dewaxing: Set the oven to 70 degrees, bake the liver tissue sections for 30 minutes, and continue to dewax with xylene for a second time; and once with alcohol (95%, 95%, 75%) for 5 minutes;

[0106] Antigen repair: Cook the slices in EDTA repair solution on an induction cooker for 20 minutes, cool to room temperature, and rinse with tap water; soak the tissue in 3% hydrogen peroxide for 30 minutes;

[0107] Blocking: Block with 5% BSA prepared in PBS for 1 hour;

[0108] Incubation with antibodies: remove the blocking solution, dilute the primary antibody with PBS at 1:200, add it to the tissue sections, and incubate overnight at 4°C; remove the primary antibody, wash 3 times with PBS, add appropriate amount of secondary antibody, incubate at room temperature for 30 min, and wash 3 times with PBS;

[0109] Color development: Prepare DAB color developing solution for color development, rinse with tap water 3 times; stain with hematoxylin for 1 minute, rinse with tap water, differentiate with 1% hydrochloric acid alcohol for 10 seconds, rinse with tap water; pass through 95% and 100% alcohol for 5 minutes in sequence;

[0110] Sealing: Add 3 drops of neutral resin, cover with a coverslip and absorb excess resin.

[0111] Immunohistochemistry results are shown in Figure 5 , Figure 6 .Depend on Figure 5It can be seen that SMIM45-107aa is expressed in the cytoplasm of liver cancer tissue cells, indicating that the purified SMIM45-107aa antibody has a high titer and good specificity and can be used in IHC experiments. Figure 6 This indicates that SMIM45 can also be used in IHC experiments of gastric cancer, breast cancer and intrahepatic bile duct carcinoma.

[0112] 2.3 Antibody Function Verification and Application Using Immunofluorescence

[0113] Slide: Slide the cells and culture overnight;

[0114] Fixation and permeabilization: wash twice with PBS, permeabilize with 0.01% Triton for 5 min, wash twice with PBS, and fix with pentanediol for 15 min;

[0115] Blocking: Wash 3 times with PBS, 2 min each time, and block with 5% calf serum for 30 min;

[0116] Antibody incubation: add primary antibody at 1:200, incubate at room temperature for 2 hours, wash 5 times with PBS, 2 minutes each time; add fluorescent secondary antibody at 1:500, incubate at room temperature for 1 hour, wash 5 times with PBS;

[0117] Sealing: Add a drop of DAPY-containing sealing medium on the slide, cover with a coverslip, and take photos.

[0118] Immunofluorescence results are shown in Figure 7 ,Depend on Figure 7 It can be seen that SMIM45-107aa has green fluorescence in the cytoplasm of the liver cancer cell line QGY-7701 and is located in the cytoplasm. It can be used for immunofluorescence experiments.

[0119] In summary, the obtained monoclonal antibody SMIM45-107aa has the specificity to recognize the SMIM45-107aa protein antigen and can be used for immunoblotting, immunohistochemistry and immunofluorescence experiments.

[0120] The above description is only a preferred embodiment of the present invention, and does not limit the implementation mode and protection scope of the present invention. For those skilled in the art, it should be aware that all solutions obtained by equivalent substitutions and obvious changes made using the contents of the specification and illustrations of the present invention should be included in the protection scope of the present invention.

Claims

1. An anti-human SMIM45-107aa monoclonal antibody comprising a heavy chain variable region and a light chain variable region, characterized in that: The antibody can specifically bind to SMIM45-107aa; in the monoclonal antibody, the amino acid sequence of the heavy chain variable region CDR-H1 is shown as SEQ ID No.3, the amino acid sequence of the heavy chain variable region CDR-H2 is shown as SEQ ID No.4, the amino acid sequence of the heavy chain variable region CDR-H3 is shown as SEQ ID No.5, the amino acid sequence of the light chain variable region CDR-L1 is shown as SEQ ID No.6, the amino acid sequence of the light chain variable region CDR-L2 is shown as SEQ ID No.7, and the amino acid sequence of the light chain variable region CDR-L3 is shown as SEQ ID No.

8.

2. The anti-human SMIM45-107aa monoclonal antibody according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region of the monoclonal antibody is shown in SEQ ID No.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID No.

2.

3. The anti-human SMIM45-107aa monoclonal antibody according to claim 2, characterized in that: The amino acid sequence of the heavy chain of the monoclonal antibody is shown in SEQ ID No.9, and the amino acid sequence of the light chain is shown in SEQ ID No.

10.

4. The anti-human SMIM45-107aa monoclonal antibody according to claim 3, characterized in that Both the heavy and light chains also include a constant region, which is that of murine or human IgG.

5. The anti-human SMIM45-107aa monoclonal antibody according to claim 4, characterized in that: The constant region is the constant region of IgG4.

6. A nucleotide molecule composition, characterized in that: It comprises a nucleotide molecule as shown in the sequence SEQ ID NO: 11, and a nucleotide molecule as shown in the sequence SEQ ID NO: 12; wherein the sequence SEQ ID NO: 11 encodes the heavy chain variable region of the monoclonal antibody according to claim 2; and the sequence SEQ ID NO: 12 encodes the light chain variable region of the monoclonal antibody according to claim 2.

7. An expression vector, characterized in that: The expression vector comprises the nucleotide molecule composition as claimed in claim 6.

8. A host cell comprising the expression vector according to claim 7, characterized in that: The host cell is a eukaryotic cell.

9. Use of the monoclonal antibody according to any one of claims 1 to 4 in preparing a product for detecting liver cancer, gastric cancer, breast cancer and intrahepatic bile duct cancer samples.

10. A detection product comprising the monoclonal antibody according to any one of claims 1 to 4, characterized in that: The detection product is selected from detection reagents, kits, immunohistochemistry detection and immunoblotting detection.

Citation Information

Patent Citations

  • Viral diagnostics

    CN103597098A

  • Cd33 antibodies and use of same to treat cancer

    CN104936617A

  • Binding molecules for the treatment of cancer

    US20210363273A1

  • Anti-TMEM106b antibodies and methods of use thereof

    WO2019133512A1